VIENNA—With actionable genomic alterations already being targeted by some existing approved drugs in patients with breast cancer genomic analysis was being hailed at the St Gallen Breast Cancer Conference as a way to expand the range of individualized cancer drugs by revealing more pathways responsible for breast cancer response and outcome. Farbice André MD, PhD, from the Institut Gustave Roussy in Villejuif, France, discussed the scope for bridging the gap between new genomic technologies and their application in the real world with Oncology Times reporter Sarah Maxwell.
You may also like...
Dengue vaccine is safe and effective — but not against all virus serotypes 11 Dec, 2012 Prostate Genomics—Which Patients Will Die? 20 Apr, 2017 ASCO Audio Journal of Oncology – June 6th 2006, from the ASCO Annual Meeting in Atlanta, June 2-6 5 Jun, 2006 Which High-Risk Prostate Cancers Need Multimodality Treatment? 18 Apr, 2017
- Previous story Endocrine Therapy in Premenopausal Breast Cancer: Most Effective Not Always Best
- Next story International Research and Consensus Needed to Interpret Breast Cancer Genomics Data
- COVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014